Mary Elizabeth Davis1. 1. Department of Ambulatory Nursing, Memorial Sloan-Kettering Cancer Center, New York, NY.
Abstract
PURPOSE/ OBJECTIVES: To review common tyrosine kinase inhibitors, as well as their ocular side effects and management. . DATA SOURCES: A comprehensive literature search was conducted using CINAHL®, PubMed, and Cochrane databases for articles published since 2004 with the following search terms. DATA SYNTHESIS: Tyrosine kinase inhibitors can cause significant eye toxicity. . CONCLUSIONS: Given the prevalence of new tyrosine kinase inhibitor therapies and the complexity of possible pathogenesis of ocular pathology, oncology nurses can appreciate the occurrence of ocular toxicities and the role of nursing in the management of these problems. . IMPLICATIONS FOR NURSING: Knowledge of the risk factors and etiology of ocular toxicity of targeted cancer therapies can guide nursing assessment, enhance patient education, and improve care management. Including a review of eye symptoms and vision issues in nursing assessment can enhance early detection and treatment of ocular toxicity.
PURPOSE/ OBJECTIVES: To review common tyrosine kinase inhibitors, as well as their ocular side effects and management. . DATA SOURCES: A comprehensive literature search was conducted using CINAHL®, PubMed, and Cochrane databases for articles published since 2004 with the following search terms. DATA SYNTHESIS: Tyrosine kinase inhibitors can cause significant eye toxicity. . CONCLUSIONS: Given the prevalence of new tyrosine kinase inhibitor therapies and the complexity of possible pathogenesis of ocular pathology, oncology nurses can appreciate the occurrence of ocular toxicities and the role of nursing in the management of these problems. . IMPLICATIONS FOR NURSING: Knowledge of the risk factors and etiology of ocular toxicity of targeted cancer therapies can guide nursing assessment, enhance patient education, and improve care management. Including a review of eye symptoms and vision issues in nursing assessment can enhance early detection and treatment of ocular toxicity.
Authors: Ruud van der Noll; Suzanne Leijen; Guido H G Neuteboom; Jos H Beijnen; Jan H M Schellens Journal: Cancer Treat Rev Date: 2013-02-19 Impact factor: 12.111
Authors: Frederick W Fraunfelder; Jonathan Solomon; Brian J Druker; Bita Esmaeli; Jennifer Kuyl Journal: J Ocul Pharmacol Ther Date: 2003-08 Impact factor: 2.671
Authors: Catherine Y Liu; Jasmine H Francis; Scott E Brodie; Brian Marr; Jose S Pulido; Michael F Marmor; David H Abramson Journal: Retina Date: 2014-07 Impact factor: 4.256